Plasma Inflammatory Mediators Associated with Bone Metabolism in COPD

Figures & data

Table 1.  Subject demographics N = 40

Age at Transplant*	59 ± 6 [42–69]
Gender
Female	24 (60%)
Male	16 (40%)
FEV1 %*	23.5 ± 8.3 [10.4–52.0]
GOLD
II	1 (2.5%)
III	3 (7.5%)
IV	36 (90%)
Inhaled Steroid Use	32 (80%)
Oral Steroid Use	19 (48%)
Bisphosphonate Use	21 (53%)
Pack Years	42.8 ± 19.5 [0–80.0]
Normal	2 (5%)
Osteopenia	21 (53%)
Osteoporosis	17 (42%)

*mean + standard deviation [range].

Figure 1.  Type 1 collagen C-telopeptide (CTx), a marker of bone resorption, is positively associated with amino-terminal propeptide of type 1 procollagen (P1NP), a marker of bone formation. (r = 0.84, p < 0.0001).

Table 2.  Plasma markers associated with markers of bone formation and resorption^⊥

Marker	CTx*	P-value	P1NP**	P-value
IL-2	N.S.	0.09	0.11 (+)	0.02
IL-4	0.39 (+)	0.005	0.27 (+)	0.01
TNF-α	0.31 (+)	0.04	0.27 (+)	0.04
IFN-γ	N.S.	0.30	0.10 (+)	0.02
RANTES	0.11(-)	0.01	0.08 (-)	0.02
eotaxin	0.21 (-)	0.003	0.17 (-)	0.02

^⊥Adjusted for bisphosphonate and steroid use.

*Type I collagen c-telopeptides; R² value (direction)

**Procollagen type I amino-terminal propeptide; R² value (direction)

Figure 2.  Interleukin-4 levels increase with increasing levels of type 1 collagen C-telopeptide (CTx) and amino-terminal propeptide of type 1 procollagen (P1NP).

Figure 3.  Tumor necrosis factor alpha (TNF-α) levels increase with increasing levels of type 1 collage C-telopeptide (CTx) and amino-terminal propeptide of type 1 procollagen (P1NP).